Jun Qi

Dr. Jun Qi is an Associate Professor of Medicine at Harvard Medical School and a member of the Cancer Biology Department at Dana-Farber Cancer Institute. His research focuses on developing small molecule inhibitors targeting epigenetic mechanisms for cancer therapy, notably discovering the BET bromodomain inhibitor JQ1 and advancing it to clinical trials. He leads efforts in chemical biology, including technologies like Chem-Seq, to study epigenetic regulators in diseases.

Education:
- BS in Chemistry, Fudan University
- PhD in Chemistry, University of Michigan (2006)
- Postdoctoral training at MIT (completed 2009)

Research Interests:
Dr. Qi’s work centers on understanding epigenetic writer, reader, and eraser proteins in cancer and other diseases. His lab combines synthetic chemistry, medicinal chemistry, and chemical biology to design novel therapeutics. Key areas include:
- Development of small molecule inhibitors targeting gene regulation pathways
- Epigenetic mechanisms in cancer and heart failure
- Translation of preclinical discoveries into clinical candidates

Labs/Teams:
- Qilab at Dana-Farber Cancer Institute (http://qilab.dana-farber.org)